S
O společnosti Synthon
G
Generika

Firemní tisková prohlášení

#
16 zář 2020

Mylan and Development Partner, Synthon, Win Significant EPO Ruling Related to Copaxone® 40mg/mL

read more
#
02 čvc 2019

BC Partners to Acquire Synthon International Holding B.V.

read more
#
05 říj 2017

Regulatory Approval in Europe granted for Synthon’s glatiramer acetate 40 mg/ml

read more
#
13 zář 2017

European Patent Office decides in Synthon’s favor in glatiramer patent case

read more
#
12 dub 2016

Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe

read more
#
03 srp 2015

Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis

read more
#
28 dub 2015

Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate

read more
#
09 říj 2014

Synthon Announces Filing of Glatiramer Acetate 40 mg/mL ANDA Containing a Paragraph IV Certification

read more
#
15 dub 2014

Synthon obtains European approvals for sevelamer

read more
#
27 bře 2014

Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate

read more
     Share this page
Archive